466 related articles for article (PubMed ID: 25665510)
1. Long-term survival of patients with locally advanced prostate cancer managed with neoadjuvant docetaxel and radical prostatectomy.
Zhao B; Yerram NK; Gao T; Dreicer R; Klein EA
Urol Oncol; 2015 Apr; 33(4):164.e19-23. PubMed ID: 25665510
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study.
Magi-Galluzzi C; Zhou M; Reuther AM; Dreicer R; Klein EA
Cancer; 2007 Sep; 110(6):1248-54. PubMed ID: 17674353
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer.
Dreicer R; Magi-Galluzzi C; Zhou M; Rothaermel J; Reuther A; Ulchaker J; Zippe C; Fergany A; Klein EA
Urology; 2004 Jun; 63(6):1138-42. PubMed ID: 15183967
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer.
Vuky J; Porter C; Isacson C; Vaughan M; Kozlowski P; Picozzi V; Corman J
Cancer; 2009 Feb; 115(4):784-91. PubMed ID: 19130458
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study.
Kibel AS; Rosenbaum E; Kattan MW; Picus J; Dreicer R; Klein EA; Chatta GS; Nelson JB; DiPaola RS; Roth BJ; Cookson MS; Wilding G; Jarrard DF; Beer TM; Ryan CW; Petrylak DP; Benson MC; Partin AW; Garrett-Mayer E; Eisenberger MA
J Urol; 2007 May; 177(5):1777-81. PubMed ID: 17437819
[TBL] [Abstract][Full Text] [Related]
6. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
7. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Chemotherapy Using Reduced-Dose Docetaxel Followed by Radical Prostatectomy for Patients With Intermediate and High-Risk Prostate Cancer: A Single-Center Study.
Nosov A; Reva S; Petrov S; Mamijev E; Novikov R; Veliev E; Imkamp F; Tolkach Y; Moiseenko V
Prostate; 2016 Nov; 76(15):1345-52. PubMed ID: 26864707
[TBL] [Abstract][Full Text] [Related]
9. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial.
Kim WY; Whang YE; Pruthi RS; Baggstrom MQ; Rathmell WK; Rosenman JG; Wallen EM; Goyal LK; Grigson G; Watkins C; Godley PA
Urol Oncol; 2011; 29(6):608-13. PubMed ID: 20022268
[TBL] [Abstract][Full Text] [Related]
11. Radical prostatectomy in clinically localized high-risk prostate cancer: outcome of 231 consecutive patients.
Røder MA; Berg KD; Christensen IJ; Gruschy L; Brasso K; Iversen P
Scand J Urol; 2013 Feb; 47(1):19-25. PubMed ID: 22762145
[TBL] [Abstract][Full Text] [Related]
12. Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era.
Isbarn H; Wanner M; Salomon G; Steuber T; Schlomm T; Köllermann J; Sauter G; Haese A; Heinzer H; Huland H; Graefen M
BJU Int; 2010 Jul; 106(1):37-43. PubMed ID: 20002667
[TBL] [Abstract][Full Text] [Related]
13. A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients.
Womble PR; VanVeldhuizen PJ; Nisbet AA; Reed GA; Thrasher JB; Holzbeierlein JM
J Urol; 2011 Sep; 186(3):882-7. PubMed ID: 21791342
[TBL] [Abstract][Full Text] [Related]
14. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer.
Chi KN; Chin JL; Winquist E; Klotz L; Saad F; Gleave ME
J Urol; 2008 Aug; 180(2):565-70; discussion 570. PubMed ID: 18554663
[TBL] [Abstract][Full Text] [Related]
15. The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients.
Mauermann J; Fradet V; Lacombe L; Dujardin T; Tiguert R; Tetu B; Fradet Y
Eur Urol; 2013 Jul; 64(1):19-25. PubMed ID: 22901983
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.
Pan J; Chi C; Qian H; Zhu Y; Shao X; Sha J; Xu F; Wang Y; Karnes RJ; Dong B; Xue W
Urol Oncol; 2019 Dec; 37(12):991-998. PubMed ID: 31466813
[TBL] [Abstract][Full Text] [Related]
17. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
[TBL] [Abstract][Full Text] [Related]
18. 20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer.
Mitchell CR; Boorjian SA; Umbreit EC; Rangel LJ; Carlson RE; Karnes RJ
BJU Int; 2012 Dec; 110(11):1709-13. PubMed ID: 22934913
[TBL] [Abstract][Full Text] [Related]
19. Patients aged more than 70 had higher risk of locally advanced prostate cancers and biochemical recurrence in Korea.
Kim JK; Cho SY; Jeong CW; Lee SB; Ku JH; Hong SK; Byun SS; Kwak C; Him HH; Lee SE; Jeong H
BJU Int; 2012 Aug; 110(4):505-9. PubMed ID: 22314007
[TBL] [Abstract][Full Text] [Related]
20. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
